Multiple myeloma remains a highly treatable but incurable disease. New agents with improved efficacy have increased the response to induction treatment. These agents have been adapted for use in maintenance therapy strategies to improve responses and delay relapse/progression with the ultimate goal of improved overall survival. Recent trials have shown that the immunomodulatory drugs thalidomide and lenalidomide; the proteasome inhibitor bortezomib; and the bisphosphonate zoledronate improve time to progression and overall survival. Introduction of new therapies, alone or in combination with existing agents, may lead to increased improvement and prolongation of disease control after autologous hematopoietic stem cell transplantation for transplant-eligible patients. (JNCCN 2013;11:35-42) 
combination regimens, have made a major impact on time to progression (TTP), PFS, and OS. Attaining and maintaining response have been important goals in the management of MM after autologous hematopoietic stem cell transplant (AHSCT). 1, 14 Researchers have postulated that depth of response is important in maintaining this response [15] [16] [17] [18] ; however, patients attaining very good partial responses have similar outcomes to those experiencing complete responses. 19 Target areas for improvement in the MM treatment continuum for transplant-eligible patients include induction, AH-SCT dose-intensive therapy, consolidation, and maintenance. This article focuses on the role of maintenance therapy after AHSCT.
An optimal agent for maintaining response should be effective, well-tolerated with manageable toxicities, simple to administer, and feasible for long-term administration. Older agents, including lower doses of melphalan, interferon-α, and glucocorticoids, have been used for maintenance after primary induction therapy. [20] [21] [22] [23] Their long-term use was limited by toxicity and modest efficacy, and because these agents, except for interferon-α and glucocorticoids, have not been studied in the AHSCT setting. Other treatments have been used to try to improve efficacy and determine suitability for long-term use.
Thalidomide
Thalidomide has been extensively studied in large phase III studies as a single agent or in combination with glucocorticoids. Of 5 large phase III studies, 3 showed an increase in OS in the thalidomide arm [24] [25] [26] [27] [28] (Table 1) . Three studies of maintenance therapy involving thalidomide plus glucocorticoids did not show an OS benefit. [29] [30] [31] Thalidomide maintenance seems to benefit patients with standard risk and not who do not have a deletion of chromosome 13 chromosome. 24 Two recent studies 27, 28 did not show an OS benefit, the latest 28 being a study of 1970 patients that randomized 820 who underwent transplantation to either thalidomide maintenance therapy or no maintenance. However, in patients receiving Total Therapy 2, thalidomide improved outcomes of those with cytogenetic abnormalities, but postrelapse survival was decreased compared with those not receiving thalidomide. 32 Long-term thalidomide therapy may cause neuropathy, resulting in up to a 60% discontinuation rate because of toxicity. Therefore, other agents have been considered for maintenance therapy.
Lenalidomide
Lenalidomide has been shown to be effective for salvage and induction therapy. 4, 5 It is considered a feasible maintenance treatment because it is an oral agent, has efficacy in low doses, and, as a single agent, can be given orally and has a well-defined toxicity profile. 32 The major toxicities of lenalidomide at the initiation of the maintenance studies were primarily hematologic, especially neutropenia and, to a lesser extent, thrombocytopenia and anemia. [4] [5] [6] [7] 33 The role of maintenance therapy following induction therapy without AHSCT is discussed in detail in Part II by Palumbo and Mina elsewhere in issue, including a phase III study that examined the role of lenalidomide as maintenance therapy following induction and non-AHSCT therapy. 34 This Part I describes the 2 phase III studies examining the role of lenalidomide maintenance therapy versus placebo after AHSCT in patients with newly diagnosed MM. 35, 36 Patients in both studies underwent induction therapy followed by AHSCT. All patients in the CALGB 100104 trial received a single AHSCT, and 79% of the patients in the Intergroupe Francophone du Myélome (IFM) 05-02 trial received a single AHSCT and 21% received a tandem AH-SCT. Patients in CALGB 100104 were randomized to either lenalidomide or placebo at approximately 100 days after AHSCT without consolidation. All patients in IFM 05-02 received 2 months of consolidation with lenalidomide within 100 days of AHSCT, followed by randomization to either lenalidomide or placebo. A significant improvement in TTP was seen for patients in the lenalidomide arm compared with those in the placebo arm in both CALGB 100104 ( The MRC Myeloma IX study included 1970 patients who were treated with intensive therapy (IT), including autologous hematopoietic stem cell transplant (AHSCT; n=1144) or nonintensive therapy (NIT; n=856). After induction therapy and completion of AHSCT in the IT arm, 820 IT and NIT patients were randomized to thalidomide (n=408) or no thalidomide (n=410).
Of the thalidomide maintenance arm, 245 patients received IT and 163 received NIT. For the no-maintenance arm, 247 patients received IT and 163 received NIT. 2). No difference was seen in OS in the IFM 05-02 study (73% vs. 75%), whereas a significant difference in OS was seen between the lenalidomide and placebo arms in the CALGB 100104 study (85% vs. 77%; P=.028). An increased incidence of hematologic toxicity (neutropenia and, to a lesser extent, thrombocytopenia) and second primary malignancies (SPMs; Table 3 ) occurred in the lenalidomide arm of both studies. An event-free survival (EFS) analysis that included disease progressions, deaths, and SPMs (excluding nonmelanoma skin cancers) as events showed a superior EFS for the lenalidomide arms in both studies ( Table 2 ). For the CAL-GB 100104 study, the cumulative incidence risk of SPM is greater for the lenalidomide arm compared with the placebo arm (P<.008). The cumulative incidence risk of progressive disease (P<.001) or death (P<.002) is greater for the placebo arm compared with the lenalidomide arm. For the IFM 05-02 study, the incidence of SPM was significantly related to study-group assignment, age, gender, and International Scoring System stage. Analyses are underway to more specifically determine risk factors for the development of second cancers.
Interest has been shown in the difference in the OS analyses of the 2 studies. To be eligible for the CALGB 100104 study, patients could not experience progression during induction therapy, and those progressing during induction were not eligible for study. Notably, approximately 8% of patients did not experience response to lenalidomide plus dexamethasone in the ECOG study. 5 Whether the addition of agents such as bortezomib would im- prove response and whether patients who experience poor response to lenalidomide-containing inductions would benefit from lenalidomide maintenance after AHSCT remains to be determined. The CALGB study allowed crossover from placebo to lenalidomide therapy after the primary end point (TTP) had been met in December 2009. Despite the crossover from placebo to lenalidomide, the OS benefit for lenalidomide persists as of the October 2011 analysis. This OS difference would be expected to diminish over time, because nearly all patients on-study experiencing no progression are now receiving lenalidomide. Patients on the lenalidomide arm of IFM 05-02 are no longer receiving lenalidomide because it was stopped at approximately a median of 32 months due to concerns regarding SPM. Furthermore, whether an OS benefit will occur later in the IFM 05-02 study or whether continued lenalidomide maintenance therapy is necessary to see an OS difference remains to be determined.
Bortezomib
Bortezomib is another attractive agent for long-term maintenance, because it has shown efficacy in salvage and induction therapy. [8] [9] [10] [11] [12] [13] Bortezomib is also considered a promising maintenance treatment because it has efficacy in lower doses as a single agent and has a well-defined toxicity profile, predominantly peripheral neuropathy. The maintenance dosing was twice a month instead of 4 times over 2 weeks, thus it was expected to cause less peripheral neuropathy. The dosing was intravenous and not subcutaneous, the latter of which is associated with less neuropathy; whether subcutaneous dosing would have had the same effect during maintenance is not known. 37 The recently published HOVON-65/GMMG-HD4 study showed superior PFS and OS when comparing bortezomib, doxorubicin, and dexamethasone (PAD) followed by bortezomib maintenance for 2 years versus VAD followed by thalidomide maintenance for 2 years 38 (Table 4) . At a median followup of 41 months, the median PFS for the PAD arm was 35 months versus 28 months for the VAD arm (P=.002). Using a multivariate analysis, the HR for PAD was 0.77 (95% CI, 0.60-1.00; P=.049). Selected high-risk patients with suitable donors went on to allogeneic HSCT, and patients treated in Germany received 2 transplants on this study. The patients receiving a double AHSCT seemed to have a superior OS (HR, 0.75; 95% CI, 0.57-0.97; P=.03). Patients with poor-risk cytogenetic MM benefited from bortezomib maintenance therapy, particularly those with del(17p13) and t(4;14) abnormalities. 38, 39 The induction and maintenance portions of the PAD arm both contained bortezomib, whereas the VAD arm contained no bortezomib in either induction or maintenance. Therefore, whether the presence of bortezomib in induction or maintenance had the greatest effect on PFS and OS cannot be conclusively stated.
No difference in the incidence of SPM in the 2 study arms was seen in the HOVON65/GMMG-HD4 trial; thus, bortezomib may not be associated with the development of SPM.
Zoledronate
The MRC Myeloma IX study examined different approaches to the treatment of patients with transplanteligible (intensive treatment [IT] ) and transplant-ineligible (nonintensive treatment [NIT]) MM. 40 One of the study questions asked whether intravenous versus oral bisphosphonates would have different effects on the incidence of skeletal-related events, so this form of therapy would not be considered maintenance therapy but more supportive care. All patients were randomized to intravenous zoledronate versus oral clodronate. Although the PFS for the IT arm was not different between the 2 bisphosphonate arms (25 vs. 25 Abbreviations: B bortezomib; C, clodronate; EFS, event-free survival; HR, hazard ratio; IT, intensive therapy; IV, intravenous; NIT, nonintensive therapy; MV, multivariate; OS, overall survival; PFS, progression-free survival; Z, zoledronate. a Includes deaths, progressions, and second cancers. 
Discussion
Recent studies show that after AHSCT for MM, maintenance therapy with bortezomib for 2 years or with lenalidomide or thalidomide until progression improves PFS and TTP. Zoledronate usually in combination with the previously mentioned agents improves PFS. Bortezomib, lenalidomide, thalidomide, and zoledronate therapy improve OS, although the OS benefit has not been seen in the IFM 05-02 study, and the bortezomib effect may have been from improved induction responses. Bortezomib, lenalidomide, or thalidomide as single agents can be offered as maintenance therapies after induction treatment and AHSCT, with bortezomib and lenalidomide being better tolerated for long-term use. Zoledronate can be offered along with these agents, because its use has been incorporated into these long-term maintenance studies. Thalidomide has been shown to improve PFS and OS in 3 of 5 trials, but its longterm use is limited by neurotoxicity. In the CALGB 100104 and HOVON65/GMMG-HD4 trials, the benefit of maintenance therapy may be optimal when patients experience response to the same agent as part of induction. In both the IFM 05-02 and HO-VON65/GMMG-HD4 trials, maintenance therapy with lenalidomide or bortezomib decreased the risk of progression or death in patients with high-risk cytogenetic MM. Thus, either regimen can be considered an acceptable maintenance strategy: bortezomib for 2 years or lenalidomide until progression after AH-SCT. The optimal length of maintenance therapy has not been determined. The CALGB 100104 and IFM 05-02 studies were designed to specifically answer the effect of lenalidomide maintenance on PFS with OS as a secondary end point. The IFM 05-02 study did have lenalidomide consolidation for both arms, which leads to a concern regarding lenalidomide exposure in both arms after transplant. It seems that all patient populations may have benefited from lenalidomide maintenance, but further analysis is necessary to clarify these differences.
MM and monoclonal gammopathy of unknown significance (MGUS) have both been associated with the development of acute myeloid leukemia/ myelodysplastic syndromes. 41 Patients with MGUS (who would not have received therapy) and, by inference, patients with MM, seem to have an undefined bone marrow defect, predisposing them to the development of myeloid malignancies. These studies have raised questions even as they have answered others. Determining whether specific risk factors exist for SPM and designing optimal treatment strategies to decrease these risks will be important. The HOVON65/GMMG-HD4 trial noted improved OS in the tandem transplant patients. The ongoing BMT-CTN 0702 study was designed to compare single versus tandem transplant versus single transplant followed by consolidation (ClinicalTrials.gov identifier: NCT01109004). All 3 arms are followed by a minimum of 3 years' planned maintenance lenalidomide therapy.
These are exciting times for the treatment of MM. Risk-adapted strategies can be developed for the treatment of patients with MM based on disease status, performance status, and comorbidities. 42 New agents, including carfilzomib, pomalidomide, MLN 9708, elotuzumab, and bendamustine, may be considered potential agents for maintenance therapy alone or in combination to maintain long-term disease control. 43, 44 Future studies may examine the use of new agents alone, in combination, or in sequence for maintenance therapy and the optimal length of time of maintenance therapy.
